A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT ID: NCT00327015

Last Updated: 2015-04-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1306 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive pioglitazone (rescue medication) added onto their blinded study medication

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saxagliptin and Metformin (A)

PLUS open-label pioglitazone (as needed as rescue medication)

Group Type EXPERIMENTAL

Saxagliptin

Intervention Type DRUG

Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)

Metformin

Intervention Type DRUG

Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

pioglitazone

Intervention Type DRUG

Tablets, Oral, 15-45 mg, as needed (12 months LT)

Saxagliptin and Metformin (B)

PLUS open-label pioglitazone (as needed as rescue medication)

Group Type EXPERIMENTAL

Saxagliptin

Intervention Type DRUG

Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)

Metformin

Intervention Type DRUG

Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

pioglitazone

Intervention Type DRUG

Tablets, Oral, 15-45 mg, as needed (12 months LT)

Saxagliptin and Placebo (C)

PLUS open-label pioglitazone (as needed as rescue medication)

Group Type EXPERIMENTAL

Saxagliptin

Intervention Type DRUG

Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)

Placebo

Intervention Type DRUG

Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)

pioglitazone

Intervention Type DRUG

Tablets, Oral, 15-45 mg, as needed (12 months LT)

Metformin and Placebo (D)

PLUS open-label pioglitazone (as needed as rescue medication)

Group Type ACTIVE_COMPARATOR

Metformin

Intervention Type DRUG

Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

Placebo

Intervention Type DRUG

Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)

pioglitazone

Intervention Type DRUG

Tablets, Oral, 15-45 mg, as needed (12 months LT)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saxagliptin

Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)

Intervention Type DRUG

Saxagliptin

Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)

Intervention Type DRUG

Metformin

Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

Intervention Type DRUG

Placebo

Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)

Intervention Type DRUG

pioglitazone

Tablets, Oral, 15-45 mg, as needed (12 months LT)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BMS-477118 BMS-477118

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes
* Inadequate blood sugar control
* No current treatment with other medications to lower blood sugar

Exclusion Criteria

* Major heart, liver or kidney problems
* Pregnant or breast feeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

77 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

East Bay Clinical Trial Center

Concord, California, United States

Site Status

Encompass Clinical Research

Encinitas, California, United States

Site Status

Community Clinical Trials

Orange, California, United States

Site Status

Coastal Biomedical Research Inc

Santa Monica, California, United States

Site Status

Encompass Clinical Research

Spring Valley, California, United States

Site Status

St. Joseph'S Medical Associates

Stockton, California, United States

Site Status

Clinical Therapeutics Corporation

Coral Gables, Florida, United States

Site Status

Florida Research Network, Llc

Gainesville, Florida, United States

Site Status

Fpa Clinical Research

Kissimmee, Florida, United States

Site Status

Emerald Coast Research Group

Marianna, Florida, United States

Site Status

Baptist Diabetes Associates

Miami, Florida, United States

Site Status

Middle Georgia Drug Study Center, Llc

Perry, Georgia, United States

Site Status

Cedar Crosse Research Center

Chicago, Illinois, United States

Site Status

Adviso Medical Research, Llc

Chicago, Illinois, United States

Site Status

Deerbrook Medical Associates

Vernon Hills, Illinois, United States

Site Status

Physicians Research Group

Indianapolis, Indiana, United States

Site Status

Professional Network Research Of Kansas

Wichita, Kansas, United States

Site Status

Medical Arts Research Collaborative, Llc

Excelsior Springs, Missouri, United States

Site Status

Nevada Alliance Against Diabetes

North Las Vegas, Nevada, United States

Site Status

Metrolina Medical Research

Charlotte, North Carolina, United States

Site Status

Durham Internal Medicine Assoc.

Durham, North Carolina, United States

Site Status

Down East Medical Associates

Morehead City, North Carolina, United States

Site Status

Midwest Regional Research, Inc.

Bellbrook, Ohio, United States

Site Status

Massillon Family Practice

Massillon, Ohio, United States

Site Status

Your Diabetes Endocrine Nutrition Group

Mentor, Ohio, United States

Site Status

Newark Physician Associates

Newark, Ohio, United States

Site Status

Preferred Primary Care Physicians

Uniontown, Pennsylvania, United States

Site Status

Safe Harbor Clinical Research

East Providence, Rhode Island, United States

Site Status

Internal Medicine Of Greer

Greer, South Carolina, United States

Site Status

Middle Tennessee Clinical Research

Fayetteville, Tennessee, United States

Site Status

Frontier Clinical Research, Llc.

Memphis, Tennessee, United States

Site Status

Capital Medical Clinic, Llp

Austin, Texas, United States

Site Status

Endocrine Associates

Houston, Texas, United States

Site Status

Advances In Health,Inc

Houston, Texas, United States

Site Status

Juno Research, Llc

Houston, Texas, United States

Site Status

Non Invasive Cardiovascular Pa

Houston, Texas, United States

Site Status

Tiena Health Research

Irving, Texas, United States

Site Status

Diabetes Center Of The Southwest

Midland, Texas, United States

Site Status

Hill Country Medical Associates

New Braunfels, Texas, United States

Site Status

Pearland Primary Care Associates, Llp

Pearland, Texas, United States

Site Status

Med-Cure Primary Care Physicians

Rosenberg, Texas, United States

Site Status

Gsa Research

San Antonio, Texas, United States

Site Status

Covenant Clinical Research, Pa

San Antonio, Texas, United States

Site Status

S.A.M. Clinical Research Center

San Antonio, Texas, United States

Site Status

Seven Corners Medical Research Center

Falls Church, Virginia, United States

Site Status

Salem Va Medical Ctr Research & Devlopment

Salem, Virginia, United States

Site Status

Physicians Clinic Of Spokane

Spokane, Washington, United States

Site Status

Local Institution

Belgrano, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Capital Federal, Buenos Aires, Argentina

Site Status

Local Institution

Capital Federal, Buenos Aires, Argentina

Site Status

Local Institution

Chacabuco, Buenos Aires, Argentina

Site Status

Local Institution

La Plata, Buenos Aires, Argentina

Site Status

Local Institution

Morón, Buenos Aires, Argentina

Site Status

Local Institution

San Martín, Buenos Aires, Argentina

Site Status

Local Institution

San Pedro, Buenos Aires, Argentina

Site Status

Local Institution

Zárate, Buenos Aires, Argentina

Site Status

Local Institution

Mendoza, Mendoza Province, Argentina

Site Status

Local Institution

Salta, Salta Province, Argentina

Site Status

Local Institution

Salta, Salta Province, Argentina

Site Status

Local Institution

San Juan, San Juan Province, Argentina

Site Status

Local Institution

Rosario, Santa Fe Province, Argentina

Site Status

Local Institution

Lanus Este, Tucumán Province, Argentina

Site Status

Local Institution

Buenos Aires, , Argentina

Site Status

Local Institution

Buenos Aires, , Argentina

Site Status

Local Institution

Fortaleza, Ceará, Brazil

Site Status

Local Institution

Fortaleza, Ceará, Brazil

Site Status

Local Institution

Goiânia, Goiás, Brazil

Site Status

Local Institution

Belém, Pará, Brazil

Site Status

Local Institution

Recife, Pernambuco, Brazil

Site Status

Local Institution

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Local Institution

Campinas, São Paulo, Brazil

Site Status

Local Institution

Marília, São Paulo, Brazil

Site Status

Local Institution

São Paulo, São Paulo, Brazil

Site Status

Local Institution

São Paulo, São Paulo, Brazil

Site Status

Local Institution

Aschaffenburg, , Germany

Site Status

Local Institution

Bad, , Germany

Site Status

Local Institution

Dresden, , Germany

Site Status

Local Institution

Dresden, , Germany

Site Status

Local Institution

Duisburg, , Germany

Site Status

Local Institution

Heidelberg, , Germany

Site Status

Local Institution

Künzing, , Germany

Site Status

Local Institution

Ludwigshafen, , Germany

Site Status

Local Institution

Magdeburg, , Germany

Site Status

Local Institution

Mainz, , Germany

Site Status

Local Institution

Mannheim, , Germany

Site Status

Local Institution

Saarbrücken, , Germany

Site Status

Local Institution

Vellmar, , Germany

Site Status

Local Institution

Wangen, , Germany

Site Status

Local Institution

Eger, , Hungary

Site Status

Local Institution

Érd, , Hungary

Site Status

Local Institution

Gyula, , Hungary

Site Status

Local Institution

Szentes, , Hungary

Site Status

Local Institution

Szigetvár, , Hungary

Site Status

Local Institution

Panjagutta, Hyderabad, Andhra Pradesh, India

Site Status

Local Institution

Vasanth Nagar, Bangalore, India

Site Status

Local Institution

Bangalore, Karnataka, India

Site Status

Local Institution

Pune, Maharashtra, India

Site Status

Local Institution

Kandivili West, Mumbai, India

Site Status

Local Institution

Sarita Vihar, New Delhi, India

Site Status

Local Institution

Chennai, Tamil Nadu, India

Site Status

Local Institution

Bangalore, , India

Site Status

Local Institution

Chennai, , India

Site Status

Local Institution

Haryāna, , India

Site Status

Local Institution

Rajasthan, , India

Site Status

Local Institution

Rajasthan, , India

Site Status

Local Institution

Vellore, Tamilnadu, , India

Site Status

Local Institution

Catania, , Italy

Site Status

Local Institution

Genova, , Italy

Site Status

Local Institution

Milan, , Italy

Site Status

Local Institution

Perugia, , Italy

Site Status

Local Institution

Ravenna, , Italy

Site Status

Local Institution

Aguascalientes, Aguascalientes, Mexico

Site Status

Local Institution

Aguascalientes, Aguascalientes, Mexico

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Mexico City, Mexico City, Mexico

Site Status

Local Institution

Cuernavaca, Morelos, Mexico

Site Status

Local Institution

Garza García, Nuevo León, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

Mérida, Yucatán, Mexico

Site Status

Local Institution

Cebu City, , Philippines

Site Status

Local Institution

Iloilo City, , Philippines

Site Status

Local Institution

Manila, , Philippines

Site Status

Local Institution

Marikina City, , Philippines

Site Status

Local Institution

Pasig, , Philippines

Site Status

Local Institution

Quezon City, , Philippines

Site Status

Local Institution

Gniewkowo, , Poland

Site Status

Local Institution

Gorzów Wielkopolski, , Poland

Site Status

Local Institution

Izabelin, , Poland

Site Status

Local Institution

Krakow, , Poland

Site Status

Local Institution

Lublin, , Poland

Site Status

Local Institution

Michalow-Regionow, , Poland

Site Status

Local Institution

Warsaw, , Poland

Site Status

Local Institution

Wroclaw, , Poland

Site Status

Local Institution

Zabrze, , Poland

Site Status

Local Institution

Carolina, , Puerto Rico

Site Status

Local Institution

Ponce, , Puerto Rico

Site Status

Local Institution

Ponce, , Puerto Rico

Site Status

Local Institution

Rio Pieoras, , Puerto Rico

Site Status

Local Institution

San Juan, , Puerto Rico

Site Status

Local Institution

San Juan, , Puerto Rico

Site Status

Local Institution

Kemerovo, Russia, Russia

Site Status

Local Institution

Moscow, Russia, Russia

Site Status

Local Institution

Moscow, Russia, Russia

Site Status

Local Institution

Moscow, Russia, Russia

Site Status

Local Institution

Nizhny Novgorod, Russia, Russia

Site Status

Local Institution

Izhevsk, , Russia

Site Status

Local Institution

Kirov, , Russia

Site Status

Local Institution

Krasnodar, , Russia

Site Status

Local Institution

Krasnodar, , Russia

Site Status

Local Institution

Kursk, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Nizhny Novgorod, , Russia

Site Status

Local Institution

Novosibirsk, , Russia

Site Status

Local Institution

Novosibirsk, , Russia

Site Status

Local Institution

Perm, , Russia

Site Status

Local Institution

Rostov-on-Don, , Russia

Site Status

Local Institution

Rostov-on-Don, , Russia

Site Status

Local Institution

Saint Peterburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saratov, , Russia

Site Status

Local Institution

Saratov, , Russia

Site Status

Local Institution

Saratov, , Russia

Site Status

Local Institution

Saratov, , Russia

Site Status

Local Institution

Smolensk, , Russia

Site Status

Local Institution

Tuymen, , Russia

Site Status

Local Institution

Vladimir, , Russia

Site Status

Local Institution

Volgograd, , Russia

Site Status

Local Institution

Volgograd, , Russia

Site Status

Local Institution

Yaroslaval, , Russia

Site Status

Local Institution

Yaroslavl, , Russia

Site Status

Local Institution

Dniepropetrovsk, , Ukraine

Site Status

Local Institution

Kharkiv, , Ukraine

Site Status

Local Institution

Kharkiv, , Ukraine

Site Status

Local Institution

Kyiv, , Ukraine

Site Status

Local Institution

Kyiv, , Ukraine

Site Status

Local Institution

Lutsk, , Ukraine

Site Status

Local Institution

Lviv, , Ukraine

Site Status

Local Institution

Lviv, , Ukraine

Site Status

Local Institution

Odesa, , Ukraine

Site Status

Local Institution

Ternopil, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Germany Hungary India Italy Mexico Philippines Poland Puerto Rico Russia Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009 Jun;11(6):611-22. doi: 10.1111/j.1463-1326.2009.01056.x.

Reference Type BACKGROUND
PMID: 19515181 (View on PubMed)

Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.

Reference Type DERIVED
PMID: 32501595 (View on PubMed)

Cook W, Minervini G, Bryzinski B, Hirshberg B. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgrad Med. 2014 Oct;126(6):19-32. doi: 10.3810/pgm.2014.10.2818.

Reference Type DERIVED
PMID: 25414932 (View on PubMed)

Karyekar CS, Frederich R, Ravichandran S. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract. 2013 Aug;67(8):759-67. doi: 10.1111/ijcp.12212. Epub 2013 Jun 24.

Reference Type DERIVED
PMID: 23795975 (View on PubMed)

Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011 Jun;13(6):567-76. doi: 10.1111/j.1463-1326.2011.01385.x.

Reference Type DERIVED
PMID: 21342412 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV181-039

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.